Synta Pharmaceuticals Corp. (NASDAQ:SNTA) Stock Quotes and News

Synta Pharmaceuticals Corp. (SNTA) 7.49 0.01

Price Open:	7.55	Day's Range:	6.56000 - 11.77400
Price Close:	7.49	52wk Range:	3.10 - 11.77400
Price Day Change:	0.01	Volume:	548,537
Price % Change:	0.13	Market Cap:	517.7M
Bid:	7.46000	PE Ratio:	0
Ask:	7.49000	EPS Diluted:	-1.097

Trade SNTA NOW!

The Latest On SNTA

Mid-Afternoon Market Update: Markets Rise Higher, Synta Pharmaceuticals Falls 3/14/13 3:44pm

Earnings Scheduled For March 14, 2013 3/14/13 4:25am

Synta Pharmaceuticals Announces Proposed Registered Direct Offering of Common Stock 12/12/12 5:05pm

UPDATE: Jefferies Raises PT to $22 on Synta Pharmaceuticals on GALAXY Update 10/1/12 12:20pm

Synta Pharmaceuticals Provides Updated Results from Phase 2b/3 GALAXY Trial 10/1/12 7:09am

UPDATE: Stifel Nicolaus Initiates Synta Pharmaceuticals at Hold; Enthusiasm Outpaces Expectations 8/30/12 1:02pm

Synta Announces $25.8 Million Registered Direct Offering of Common Stock 7/26/12 7:34am

Synta Announces Results from Interim Analysis of the Randomized Phase 2b/3 GALAXY Trial Evaluating Ganetespib plus Docetaxel in Second-Line Non-Small Cell Lung Cancer 6/27/12 4:06pm

UPDATE: Jefferies Raises PT on Synta from $7 to $14 6/25/12 2:33pm

Stocks Hitting 52-Week Highs 6/25/12 10:51am

UPDATE: Jefferies & Company Reiterates Buy Rating, Raises PT for Synta Pharmaceuticals 6/25/12 10:44am

UPDATE: BMO Capital Markets Upgrades Synta Pharmaceuticals to Outperform on HSP90 Opportunity 6/4/12 2:45pm

Press Releases

Synta Announces Presentations at the 2013 American Society for Clinical Oncology (ASCO) Annual Meeting 5/15/13 Business Wire

Synta Announces First Patients Treated in Pivotal GALAXY-2 Trial Evaluating Ganetespib in Advanced Non-Small Cell Lung Cancer 4/22/13 Business Wire

Synta to Host Conference Call and Webcast of First Quarter 2013 Financial Results on April 30, 2013 4/16/13 Business Wire

Synta Announces Presentations at the 2013 Annual Meeting of the American Association of Cancer Research 4/5/13 Business Wire

Synta Provides Company Updates and Reports Fourth Quarter and Year-End 2012 Financial Results 3/14/13 Business Wire

Synta Announces Appointment of Sumant Ramachandra, M.D., Ph.D. as President, Research and Development 3/13/13 Business Wire

Synta to Host Conference Call and Webcast of Fourth Quarter and Year-End 2012 Financial Results on March 14, 2013 2/25/13 Business Wire

Synta to Present at Upcoming Conferences 2/11/13 Business Wire

Synta Pharmaceuticals Announces $60 Million Registered Direct Common Stock Offering 12/13/12 Business Wire

Synta Pharmaceuticals Announces Proposed Registered Direct Offering of Common Stock 12/12/12 Business Wire

Synta Pharma: Poised For A Breakout With 4 Near Term Catalysts 12/11/12 PR Thomson Reuters

Synta to Present at the Deutsche Bank 2012 dbAccess BioFEST 11/27/12 Business Wire

Get the latest SNTA stock news on the web. Get the latest stock quotes and much more - Benzinga is the source for Synta Pharmaceuticals Corp. stock price.

Partner Headlines

Synta Pharmaceuticals Inc. (SNTA) CEO Safi R Bahcall buys 10,000 Shares 11/13/12

Synta Pharmaceuticals, Inc. (SNTA) CEO Safi R Bahcall buys 10,000 Shares 11/13/12

Synta Pharmaceuticals Inc. Reports Operating Results (10-Q) 11/6/12

Billionaire Investor Buys at Synta (MRK, JNJ, LLY) 7/9/12

Weekly CEO Buys Highlight: SNTA, MEI, PZG, MCHX, CMXI 7/7/12

Synta Pharmaceuticals Inc. (SNTA) CEO Safi R Bahcall buys 10,000 Shares 7/2/12

Health Care Sector Wrap 6/28/12

Teva Pharmaceutical Industries, Constellation Brands Among Stocks Up on High Volume Monday 6/25/12

Quest Software, Pharmacyclics, Other Stocks Hit 52-Week Highs Monday 6/25/12

Merck &, Onyx Pharmaceuticals Among Stocks Hitting 52-Week Highs Friday 6/22/12

New Lease Agreements for Alexandria - Analyst Blog 6/8/12